In the latest update on Dianthus Therapeutics (DNTH, Financial), analyst Joel Beatty from Baird has maintained a consistent rating on the stock. The rating remains at "Outperform," reflecting a positive outlook on DNTH's market performance despite recent adjustments.
However, Baird has lowered its price target for DNTH from the previous $58.00 USD to a new target of $50.00 USD. This adjustment represents a 13.79% decrease in the projected value of the stock, indicating a reassessment of the company's future valuation.
Dianthus Therapeutics (DNTH, Financial) continues to trade on the NASDAQ, and this update from Baird, dated May 13, 2025, is one of the latest notable changes in analyst predictions for the company's financial trajectory. Investors may consider this information as part of their broader investment strategy regarding DNTH.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 9 analysts, the average target price for Dianthus Therapeutics Inc (DNTH, Financial) is $47.78 with a high estimate of $56.00 and a low estimate of $34.00. The average target implies an upside of 137.94% from the current price of $20.08. More detailed estimate data can be found on the Dianthus Therapeutics Inc (DNTH) Forecast page.
Based on the consensus recommendation from 12 brokerage firms, Dianthus Therapeutics Inc's (DNTH, Financial) average brokerage recommendation is currently 1.5, indicating "Buy" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
